Purpose: Transgenic mouse models are proving to be invaluable in our effort to understand the molecular basis of metastatic prostate cancer (CaP). We review and discuss how current animal models have contributed to our understanding of the metastatic cascade and how transgenic technology is being used to develop the next generation of mouse models. Our goal is to provide a review of the recent advances and provide a framework for further studies. Materials and Methods: We performed a MEDLINE search of the literature on CaP metastasis transgenic and animal models. Results: We present a summary of the characteristics of nine different animal models of CaP. Each model is unique and provides valuable insight into the molecular mechanisms governing the progression of CaP. Our experience with transgenic models and all the new data from the literature predicts that we will be able to develop genetically engineered mice that accurately mimic the heterogeneity, androgen-independent growth, and metastatic spread seen in clinical disease. Conclusion: In order to elucidate the molecular mechanisms of CaP metastasis, it will be necessary to compare gene and protein expression patterns and biochemical analyses of clinical metastatic disease with data obtained from current models. We will also need to refine our ability to engineer and characterize genetic perturbation models. This type of integrative and iterative approach should facilitate better understanding of the molecular biology of CaP metastases.
Introduction
Prostate cancer (CaP) is the second leading cause of cancer deaths of men in the United States, 1 and the vast majority of CaP deaths are related to metastatic disease. In fact, of the early 9 000 American men that will die from CaP this year, greater than 70% will succumb to complications resulting from late-stage tumors that have spread to distant sites. 2 Unfortunately, there are few treatment options for patients with advanced CaP. Despite advances in androgen ablation therapies, the cancer will often progress to an androgen independent (AI) metastatic stage. 3 Consequently, there is intense effort to understand the molecular mechanisms responsible for the progression of androgen-dependent (AD) disease and the emergence of AI and metastatic CaP.
It has been difficult to study the natural history of CaP at the molecular level and rapidly develop effective treatment strategies, in part, because there are so few animal models that accurately mimic the heterogeneity, AI growth and metastatic spread of clinical disease. To circumvent this problem, researchers have historically exploited immortalized human CaP cell lines, such as LNCaP and DU-145, to elucidate the biology of tumor progression, AI disease, and metastasis. [4] [5] [6] [7] However, clonal cell lines in culture limit our ability to study the dynamic interactions between the various cellular compartments that comprise the intact prostate gland, such as the stromal, endothelial and luminal basal, and neuroendocrine NE epithelial cells. Furthermore, employing cell lines in vivo necessitates the use of immunodeficient host mice that, a priori, provide limited utility in immunologic studies. From this and other points of view, it would be clearly advantageous to study an autochthonous model in which the tumor develops spontaneously in a genetically defined and immunocompetent background. It is anticipated that such models would facilitate studies to elucidate the molecular changes that allow cells to become invasive and progress through the process of metastogenesis. 8 In this review, we will discuss the features of metastatic CaP and how current animal models have contributed to our understanding of the metastatic cascade. Also, we will address how transgenic technology is being used to develop the next generation of mouse models. Our goal is to provide a review of the recent advances and provide a framework for further studies.
Methods
We performed a MEDLINE search of the literature using prostate, metastasis, and transgenic as keywords. We relied primarily on our own experience with transgenic mouse systems as well as on recent articles and reviews pertaining to animal models of CaP and the articles referenced therein.
The metastatic cascade
The formation of a metastatic lesion is the result of a complicated, multistep process that is collectively referred to as the metastatic cascade. 8 By this scheme, the nutritional requirements of a growing tumor likely exceed the available blood supply, leading to establishment of a localized hypoxic state that in turn triggers an angiogenic switch. 9 The result is angiogenesis, a host response that facilitates neovascularization. As a consequence, and with continued tumor growth, some cells will lose expression of cell-cell adhesion molecules, such as E-cadherin, 10 and express matrix metalloproteinases (MMPs), such as MMP2, 11 which will allow them to detach from the primary tumor site and invade through the basement membrane. Subsequently, the invasive cells may enter the lymphatic or hematogenous circulation where they can be carried to distant sites. In order to avoid detection by the immune system, it is believed that metastatic cells form aggregates with other cells as well as with fibrin deposits and platelets. 12 Ultimately, the metastatic cells extravasate across the blood vessel endothelium and invade the extracellular matrix at the distant site. It is generally accepted that the metastatic cascade can only be complete if the microenvironment at the distant site is suitable for the establishment of a viable macroscopic metastatic lesion. Clearly, the availability of an animal model that reproducibly and systematically recapitulated all the events in the metastatic cascade would contribute significantly to our understanding of human CaP biology.
In clinical CaP, bone is the primary metastatic site. The second most common site of metastasis is the liver, followed by the lungs and adrenal glands. 13 There are at least two different theories to explain the prevalence for secondary-site bone metastases. One theory is based on a study of over 19 000 CaP patients where metastases were most frequently observed in the spine, followed by the ribs, and in a few cases, the peripheral skeleton and skull. 13 This study suggested that the pattern of blood flow from the prostate determined the location and frequency of metastasis and that cancer cells from the prostate travel through the blood stream via a portal-like venous system that shuttles blood between the spine and the prostate. A second theory, based on Paget's 'seed and soil' hypothesis, 14 is supported by data from an innovative transplant model in which the humanized nonobese diabetic/severe combined immunodeficient (NOD/SCID-hu) mice were engrafted with human adult bone and lung tissues and then received tail vein injections of LNCaP tumor cells. The fact that the cells were observed to preferentially metastasize to the engrafted human bone, and not to mouse bone or human lung, 15 suggests that there are components of metastasis that are both tissue and species specific. The data also imply that a circulating tumor-derived cell, through an unknown mechanism, exploits the native environment in order to establish a colony and become a viable metastatic lesion.
The demonstration by Koeneman et al 16 that human LNCaP lineage-derived cell lines (C4, C4-2, and C4-2B) acquire the ability to express bone matrix noncollagenous proteins and become osteomimetic, or bone-like, further supports the seed and soil hypothesis. Other groups have further shown that CaP cells can produce growth factors that stimulate osteoblastic bone production. 17 Clearly, it remains an important goal to resolve and identify the individual 'seed and soil' factors that facilitate the selective adherence to and subsequent colonization of distant sites.
It has been demonstrated in vivo that a secondary-site micrometastatic lesion is actually dependent on the surrounding non-native stroma or mesenchyme for survival and growth. 18 The stromal dependence of tumor cells has also been demonstrated using in vitro bone marrow stromal cells that were capable of stimulating growth of cells derived from malignant prostate epithelium. 19 It is believed that the tumor cells induce the surrounding stromal cells to express survival factors in a paracrine positive-feedback loop. A current and popular method to identify the factors that mediate crosstalk between the local stromal compartment and a proliferating micrometastatic lesion is to compare gene expression patterns between proliferating metastatic cells and nonproliferating tumor cells. It is anticipated that this technique will help to describe genes and pathways responsible for the growth advantage phenotype of proliferating secondary site metastases.
A new class of genes, the metastasis suppressor genes, have been isolated and appear to play important roles in the progression of CaP from a nonmetastatic to a highly metastatic state. In contrast to tumor suppressor genes that inhibit tumor growth, metastasis suppressor genes are believed to inhibit the formation of macroscopic metastases at distant sites. 20 The first evidence for the existence of metastatic suppressor genes was demonstrated by Ichikawa et al, in a series of cell fusion experiments using nonmetastatic Dunning rat CaP cells and highly metastatic Dunning rat CaP cells. In these studies, only the clones that had lost a normal copy of chromosome 2 were able to develop distant metastatic lesions following tail vein injections. 21 Clearly, a factor expressed from the lost region of chromosome 2 was responsible for inhibiting the ability of the cells to form viable cell clusters at a distant site. Similar experiments have subsequently led to identification of potential metastasis suppressors, such as CD44, 22 NME1, 23 Mkk4/SEK1, 24 and KAI1. 25 Identification, isolation, and characterization of such modifiers of metastasis are a critical priority for both diagnosis and treatment of CaP.
An important step towards increasing the utility of transgenic models of CaP will be the identification of factors involved in formation of a viable metastatic lesion and characterization of those factors responsible for proliferation of that lesion to form a macrometastasis. These factors can then be exploited to overcome the low frequency of bone metastases in currently available CaP transgenic mouse models and to develop models that better imitate the latter stages of the human disease. Thus far, transgenic technology has produced many useful models of CaP that have provided for identification of factors involved in cellular transformation at the onset of cancer and tumor angiogenesis. These models have also contributed immensely to understanding hormone regulation of tumor growth. In the following section we discuss the current animal models of CaP that display metastatic potential and how they can be utilized to provide insight into clinical disease.
Models of metastatic CaP
In the following section we will review the currently available animal models that exhibit metastatic CaP. The numerous human xenograft and cell inoculation models, as well as the animal models of CaP that do not display metastatic disease, are beyond the scope of this review. It is anticipated that continued investigations into the genes and pathways known to influence metastasis and a thorough characterization of the current models will empower both our near-term studies to elucidate the molecular mechanisms that initiate CaP metastasis, and our long-term goals to design improved models to develop prevention, diagnosis, and intervention protocols for the future.
Spontaneous/chemically inducible models
The Lobund-Wistar rat. The Lobund-Wistar rat is a very well-characterized model of CaP (reviewed in Pollard). 26 Derived from the 57th generation of inbred germ-free Wistar rats, the Lobund-Wistar strain develops large tumors in the dorsolateral and anterior lobes of the prostate, as well as the seminal vesicles. These 'P-SV' tumors have been observed to develop spontaneously in 27% of Lobund-Wistar rats at a mean age of 26 months. These tumors become AI and metastasize primarily to the lungs. To date, Lobund-Wistar rats are the only known rodent strain that develops spontaneous hormone-sensitive metastatic prostate adenocarcinomas. The long latency period may be particularly beneficial in studies involving the modification of latency and/or percentage of incidence by factors such as chemical induction or dietary restriction, but it is problematic for investigators wishing to focus primarily on late-stage events such as metastasis. The low incidence of primary cancer in this model necessitates larger cohorts; however, administration of a combination of methylnitrosourea and testosterone propionate can increase the incidence of P-SV tumors to 90% and reduce tumor latency to 8.5 months following initial treatment. 27 While involvement of the seminal vesicles in Lobund-Wistar tumors and the lack of osseous metastases are inconsistent with clinical disease, the Lobund-Wistar rat has a unique utility in elucidating the spontaneous events leading to androgenindependence and metastasis.
The Fischer F344 rat. When chemically induced with a combination of 3,2 0 -dimethyl-4-aminobiphenyl and testosterone propionate, Fischer F344 rats commonly develop noninvasive cancers in the dorsolateral and anterior lobes of the prostate, as well as seminal vesicles. 28 Although distant site metastases have been observed in this model, they are rare and mostly confined to the abdominal cavity. Fischer rats have historically been used to study induction of CaP by carcinogens, but are not well characterized with respect to metastatic properties.
The Dunning R-3327 system. The original Dunning R-3327 tumor arose as a spontaneous adenocarcinoma in the prostate of an inbred Copenhagen rat. 29 Although the original tumor was nonmetastatic and had a welldifferentiated phenotype, serial propagation has led to the establishment of numerous derivative tumors and cell lines. These materials phenotypically represent a wide range of cancers with respect to progression, growth rates, androgen receptor status, androgen sensitivity, histologic state, and metastatic ability (summarized by Isaacs 30 ). The AT-3, AT-6, MAT-Lu, and MATLyLu lines are the four commonly used metastatic cell lines derived from the Dunning tumor. These lines are well characterized from a biochemical and genetic standpoint, and reproducibly demonstrate metastases to lymph node and lung when grafted into syngeneic or immunodeficient recipients. Tail vein inoculation of MAT-LyLu cells into Copenhagen rats can result in reproducible skeletal metastases to lumbar vertebrae, 31 and these metastases can demonstrate osteoclastic and osteoblastic activity, consistent with clinical CaP. Generally, the inherent malignant potential of the R-3327 cell lines precludes the examination of spontaneous events leading to initiation of cancer. However, these lines are useful for studying processes affecting androgen sensitivity. Furthermore, with respect to metastogenesis, the various cell lines are of great utility in experiments involving how specific factors may enhance or prevent the establishment and growth of tumors at secondary sites.
Canines. Dogs are the only species besides humans that develop spontaneous CaP with high frequency. Canine CaP has a high propensity for metastasis, with secondary carcinomas detectable in approximately 80% of CaP diagnoses. 32 The most common sites of metastatic spread are regional lymph nodes, lung, and bone, including the pelvis, lumbar vertebrae, femur, and humerus. Interestingly, the incidence of bone metastases is estimated to be greater than 24%. 32 This relatively high frequency of osseous metastases and the commonly observed osteoblastic phenotype are characteristics shared with human CaP. 33 Diagnosis of canine CaP is also age-dependent. Interestingly, the high prevalence of carcinoma in castrated dogs does not parallel the data obtained from human eunuchs and this raises questions as to the androgen-dependence of canine CaP. In fact, canine tumors have not been reported to respond to androgen deprivation therapy, possibly owing to the fact that most diagnoses occur once the disease has progressed to a relatively late stage. However, the incidence of highgrade prostatic intraepithelial neoplasia in dogs is known to be influenced by androgens. 34 Overall, the high frequency of spontaneous carcinoma and distant site metastases, particularly skeletal, makes the canine an attractive model for future studies focusing on metastatic processes. The larger size of dogs as compared with other model species also facilitates the use of a wider variety of imaging techniques, many of which have been reviewed by el-Gabry et al. 35 Canine models are also advantageous in preclinical evaluation of therapeutic techniques, specifically those targeting bone metastases, since these are difficult to implement in smaller organisms. Hence, the main limitations of canine model systems are a relatively long latency period, questionable role of androgens, and the high cost of maintaining dog colonies.
Transgenic models
Transgenic models of CaP were first generated in the mid-1990s and are fast becoming the models of choice for investigators focusing on metastatic processes. In general, transgenic models feature higher penetrance, faster progression, and greater overall reproducibility of metastatic properties compared to spontaneous or induced models. Here we will review those published transgenic models that display metastatic potential (see Table 1 ).
PB(À426/+28)/SV40 T,t (TRAMP).
The TRAMP (transgenic adenocarcinoma of the mouse prostate) model, developed in our laboratory, is based on a minimal rat probasin (PB) promoter directing expression of the heterologous simian virus 40 (SV40) early genes (T, t antigen; Tag) specifically to the mouse prostatic epithelium. Expression of Tag effectively abrogates the functional expression of p53 and retinoblastoma (Rb) proteins that have previously been implicated in human disease. 36, 37 Consistent with the spatial and temporal expression pattern of the rat PB gene, PB-Tag expression begins between 4 and 6 weeks of age, and TRAMP mice consequently develop mild to severe hyperplasia by 12 weeks of age. At 24 weeks of age, approximately 100% of male mice have poorly differentiated and invasive adenocarcinomas. Lymph node and lung metastases are common in these mice, and metastases to bone, kidney, and adrenal glands are also observed. 38 Castration of TRAMP mice at 12 weeks of age causes an initial regression of the prostate, indicating that tumors are initially androgen sensitive. Castration at 12 weeks is curative in approximately 20% of TRAMP mice, but the remainder eventually progress to poorly differentiated androgen-insensitive cancer with frequent metastases by 24 weeks of age. 39 Interestingly, skeletal metastases are only observed in {C57 TRAMP Â FVB} F1 mice, but not in the pure C57Bl/6 background. Therefore, we are currently comparing TRAMP mice in these two genetic backgrounds to identify genes that can modify the ability of CaP cells to metastasize to bone. Similarly, we are using SAGE and large-scale cDNA-and oligo-based microarray analyses using paired tissues collected from both primary tumor and lymph node metastases in TRAMP mice to elucidate sets of specific genes which, when differentially expressed, promote a metastatic phenotype. Several immortalized epithelial cell lines have been isolated from TRAMP, ranging from nontumorigenic to aggressively metastatic, 40 to facilitate immunologic studies in vivo as well as in vitro experiments to screen potential metastasis-inhibiting compounds.
Salient features of the TRAMP model include 100% incidence of disease, recapitulation of the histologic progression from PIN to invasive carcinoma observed in humans, reproducible metastases, and initial androgen sensitivity that progresses toward androgen independence following androgen deprivation. More recently we have described the emergence of a NE phenotype in the TRAMP model, a characteristic associated with more advanced cancer. 41 Furthermore, TRAMP is, to our knowledge, the first model to display the phylloideslike phenotype observed clinically in both prostate and breast cancer, which consists of a staghorn luminal structure, intraductal proliferation of high-grade PIN, nuclear atypia, and intense stromal proliferation. 42 The approximate 30-week time course of CaP progression in TRAMP facilitates prevention, intervention, or regression trials, and ensures that these experiments can be performed in a timely manner.
PB(À11.5 kb/+28)/SV40 T (LADY).
A larger fragment of the 5 0 flanking region of the rat probasin promoter (LPB) has been used to direct expression of only the SV40 large T antigen to the prostate epithelium. Seven lines of these 'LPB-Tag' mice have been generated and are collectively called the 'LADY' system. Six of the seven lines develop AD carcinomas that rarely metastasize, but one line, 12T-10, exhibits reproducible metastases with both glandular and NE characteristics. 43 In the normal human and mouse prostate, NE cells represent a small percentage of the epithelial cells, especially when compared to basal or luminal types. 44 However, the NE differentiation of CaP has recently received increased attention, and it has been reported that 30-100% of human CaP cases show some degree of NE differentiation. 41 The 12T-10 line develops precursor lesions that are histologically similar to human PIN, and eventually develops invasive carcinoma. Metastatic frequency is 66% in mice at 6 months of age, and 88% at 9 months, commonly targeting regional lymph nodes, liver, and lung. 43 Skeletal metastases have not been reported. Interestingly, the high mitotic activity of NE cells in the 12T-10 line resembles that seen in small cell carcinoma of the prostate in humans. This contrasts to the relatively low mitotic rate of NE cells in prostate adenocarcinoma, raising the possibility that the 12T-10 line may be especially useful in elucidating the processes involved in initiation and progression of small cell carcinoma.
PSP94/SV40 T,t. A 3.8 kb region of the prostate secretory protein of 94 amino acids (PSP94) promoter has recently been used to generate transgenic mice expressing SV40 Tag in the prostate epithelium of the three lines characterized. 45 Tag expression was not detected in the anterior prostate or seminal vesicles. Three breeding lines designated A, B, and C were established and at approximately 10 weeks of age all male mice were found to develop hyperplasias that progress to well-differentiated adenocarcinoma by 24 weeks. Foci of poorly differentiated cancer were observed as early as 16 weeks in line A and 28 weeks in line C. Androgen dependence was demonstrated by castration for 1 month, at which time 66% of mice from line A were found to develop hormone-refractory tumors. Although no metastases were reported in lines B and C, 100% of line A males examined (n ¼ 3) demonstrated metastases of prostatic origin in the regional lymph nodes and kidney. 45 Even though the full spectrum of disease in PSP94/Tag mice is still being characterized, a strong metastatic potential has been demonstrated in at least one line.
In addition to models based on the prostate-specific rat PB and PSP94 promoters, transgenic models have also been generated using regulatory elements derived from the rat prostatic steroid binding protein [C3(1)] gene, cryptdin-2, and fetal g-globin to drive expression SV40 T antigen. As discussed in the next sections, these promoters have not proven to be intrinsically prostatespecific, but the resulting transgenic mice have been shown to develop prostate carcinoma with metastases.
C3
(1)/SV40 T, t. Mice have been generated using a 4.5 kb fragment of the rat prostatic steroid binding protein [C3 (1)] gene driving expression of the SV40 early region. 46 Female mice develop mammary adenocarcinoma by 6 months of age, and this model has consequently received considerable attention as a transgenic model of breast cancer. Male mice develop prostate hyperplasias as early as 3 months of age, and the majority progress to adenocarcinomas at approximately 8 months of age. The adenocarcinomas are generally locally invasive and one lung metastasis has been reported. 46 One limitation of this model is that transgene expression is routinely detected in other tissues including thyroid and salivary gland. This has been attributed to the lack of certain regulatory elements in the 5 0 fragment of the C3(1) regulatory region that may be necessary to restrict Tag expression exclusively to the prostate. In summary, although CaP metastases have been observed, the actual frequency in this model is unknown and these mice are still being characterized in this respect.
Cryptdin-2/SV40 T. A À6500 to +34 base pair fragment of the mouse cryptdin-2 promoter was used to direct expression of SV40 large T antigen. The original intent of this construct was to direct T expression to the Paneth cells found in intestinal crypts, 47 but these mice unexpectedly developed prostate tumors and secondary-site metastases arising from the NE cells of the prostate. 48 Foci resembling PIN were observed as early as 8 weeks of age, and by 12 weeks all mice developed multifocal PIN. By 16 weeks, 90% of mice displayed locally invasive carcinoma, and by 24 weeks, 100% of mice had large solid prostate tumors. Additionally, 40% of mice had metastases that were found in lymph node, liver, lung, and bone.
The NE phenotype of the primary tumors in these mice was confirmed by immunostaining with two NE markers, chromogranin A (a marker also expressed in primary tumors of LPB-Tag 12T-10 mice 43 ) and synaptophysin. It is important to note that the cryptdin-2 Tag mice do not respond to androgen deprivation. In fact, castration of these mice results in a decrease in both weight and volume of the prostate because of atrophy of the untransformed androgen-sensitive cells in the prostate, but with no apparent influence on the observed NE lesions. This finding does, however, provide support for the hypothesis that castration provides a selective advantage for certain subpopulations of cells in the prostate, such as the AI NE cells, which can proliferate and metastasize readily and remain insensitive to hormonal therapy. Since the carcinomas are NE in origin, this precludes the examination of the spontaneous events that might initiate an epithelial transition towards the NE phenotype.
Fetal Gg-globin/SV40 T. Transgenic mice have been generated with the human fetal Gg-globin promoter driving expression of the SV40 large T antigen. Intended to target erythroid cells in the mouse, expression of the Gg/T construct unexpectedly caused prostate tumors at 5-7 months of age. 49 Prostatic expression of the transgene has been attributed to cryptic DNA cis regulatory elements activated in the prostate. Penetrance is 100% in homozygous transgenic mice. Prostate tumors are described as having a mixed epithelial and NE appearance, supported by expression of both cytokeratin 8 and chromogranin A. 50 Androgen dependence in this model differs from that seen in humans in that tumors either progress very rapidly towards an AI state or arise as such. However, since large T antigen was expressed in adult, but not fetal or neonatal prostate, this supports the role of androgens in carcinogenesis. Metastases in these mice are observed primarily in the adrenal gland and kidney, although infrequent micrometastases to lung and bone are observed. Data concerning androgen dependence of these tumors remain inconclusive, and the appearance of other nonprostatic tumors such as adrenal and brown fat tumors and seminomas complicates the task of pairing metastases with a specific tumor of origin. Owing to the mixed epithelial and NE phenotype, this model may be of great utility in examining interactions between subtypes of prostatic epithelial cells and how these contribute to cancer progression in vivo.
Metastasis and the NE phenotype
The significance of NE differentiation in clinical CaP remains unclear. NE cells are the least abundant cell type in the prostate 44 and their contributions to normal growth and development of the prostate are poorly understood. Although NE cell cancers in the prostate are rare, foci of NE-like features can be observed in nearly all prostate adenocarcinomas and extensive NE differentiation is generally considered to be of poor prognostic value. 51 NE cells lack nuclear androgen receptor 52 and are therefore considered to be androgen-insensitive, rendering hormone-based therapy largely ineffective. Indeed, NE differentiation appears more extensively in hormone-refractory cancer. 53 Furthermore, due to a lack of significant proliferative 54 or apoptotic 55 properties, current radiation and cytotoxic therapies that target cycling cells are largely ineffective against NE cells.
56
Although it is unclear whether NE cells are more likely to metastasize than their secretory cell counterparts, NE cells likely contribute to the invasive potential of prostate carcinoma cells through such mechanisms as the secretion of the neuropeptide bombesin/gastrin-releasing peptide. Bombesin has been shown to increase the invasive capacity of CaP cells in culture, 57 potentially through the upregulation of MMP-9, 58 both of which are expressed in clinical metastases. 59 Additionally, higher incidence of bone metastases has been reported in patients with elevated serum levels of the NE marker chromogranin A. 60 Interestingly, all of the transgenic mouse models that have a reproducibly high rate of metastasis exhibit NE features, albeit to different degrees. While TRAMP and related models stochastically exhibit an epithelial to NE transition as a function of cancer progression, 42, 43 the Cryptdin-2/SV40 T mice develop lesions that actually originate in the NE cell population and would therefore be uniquely useful in examining the in vivo roles of NE cells in the prostate. DNA microarray studies of the Cryptdin-2/SV40 T have already identified mASH1, AADC, and GABAergic pathway components as possible therapeutic targets for treatment of NE CaP. 61 The fact that these transgenics display at least some NE characteristics as observed in human CaP underscores their utility as in vivo models in which to identify novel molecular pathways involved in NE differentiation and test novel therapies directed against NE disease.
Models of the future
The challenge facing CaP metastasis research in the near future will be the improvement of existing models by incorporating perturbations of specific factors involved in the metastatic cascade (Figure 1 ). For example, MMPs degrade components of the extracellular matrix and have been implicated in tissue remodeling, tumor invasion, and metastasis, 62 with MMP2 and MMP9 receiving particular focus in the field of CaP research. The MMP proteins are negatively regulated by the tissue inhibitor of metalloproteinase (TIMP) family. As CaP cells generally express elevated levels of MMPs and low levels of TIMPs, 63 it would be interesting to examine the effects of forced misexpression of MMP2 and/or MMP9 as well as dominant-negative TIMPs within the context of an established animal model. In fact, similar experiments are already in progress utilizing cadherins, a family of proteins that mediate cell-cell adhesion. Downregulation or loss of cadherins is frequently associated with cell detachment, invasion, and metastasis. 64 Under the Figure 1 Models of the future. The next generation of models of metastatic CaP will likely integrate genes encoding metastasis factors with existing oncogene-driven models in two-component systems containing separate transactivator and responder transgenes. Such models would be tissue-specific, inducible, and reversible. Tissue specificity will be achieved by constructs that employ prostate-specific promoters to direct expression of transactivators to the prostatic epithelium. A typical transactivator is the reverse tetracycline transactivator (rtTA) that consists of the modified tetracycline repressor (rtetR) fused to a VP16 transactivation domain. This system might also employ a bicistronic responder designed to express a metastatic factor in addition to a known oncogene (ie SV40 Tag) under transcriptional control of an rtTA-responsive promoter containing a tetracycline (tet) response element (TRE). As shown in this schematic, the responder transgene would remain quiescent in the absence of the transactivator and would be specifically induced by the addition of the rtTA cofactor doxycycline (DOX).
control of the rat PB promoter, a mutant N-cadherin that lacks the extracellular domain has been expressed in the mouse prostatic epithelium. Mice carrying this transgene have been crossed with the TRAMP model, and the bigenic offspring exhibited significantly faster progression to metastatic disease as well as a marked increase in the total number of metastases to liver, lung, lymph node, bone, and other distant sites (R Morton, personal communication). Interestingly, loss of E-cadherin expression was also observed in these mice, paralleling clinical observations that loss of E-cadherin correlates with increased frequency of metastases in humans. 65 Another consideration in the design of new models will be the ability to track the progression and spread of metastases to distant sites in live animals using new reporter genes and improved imaging technology. Assaying classic reporter genes such as b-galactosidase and alkaline phosphatase commonly requires the sacrifice of the animal. However, because metastatic spread occurs at variable time points and targets a variety of secondary sites, new live imaging technologies will be advantageous in eliminating some of the guesswork involved in animal sacrifice and tissue collection, thereby allowing investigators to use each individual animal to its full potential. Bicistronic transgenes with an internal ribosome entry site 66 followed by either green fluorescent protein or luciferase can label individual cells expressing the transgene, and these can be imaged in a live animal. 67, 68 TRAMP mice with a bicistronic luciferase reporter are currently being generated in our laboratory. Another potentially useful system for live imaging is based on positron emission tomography (PET). A PET reporter gene is used to bind a positronemitting probe and sequester the radiolabel, which can then be detected in a sensitive and quantitative fashion using a microPET scanner. 69 The incorporation of realtime live imaging techniques into the next generation of metastatic CaP models will greatly enhance their utility in all phases of research, from the investigation of individual proteins and molecular pathways to preclinical trials of metastasis inhibiting compounds.
Conclusion
We have attempted to provide a clear and concise review of the literature concerning animal models of metastatic CaP, taking into account the advantages and limitations inherent in each system. In order to elucidate the molecular mechanisms of CaP metastasis, it will be necessary to combine a thorough understanding of current models with a knowledge of the ever-expanding number of genes and pathways implicated in metastatic progression. We feel that this type of integrative approach will allow us to gain maximum utility from the current models while also driving the generation of improved models for the future.
